| Oncology | |||
| NO. | Nombre del producto | Especificación | Aprobado | 
| 1 | Anastrozole | USP | DMF | 
| 2 | Bicalutamide | USP | FDA approved | 
| 3 | Bleomycin sulphate | USP | FDA/COS approved | 
| 4 | Capecitabine | Enterprise standard | GMP/EDMF | 
| 5 | Carboplatin | USP/EP | GMP/EDMF | 
| 6 | Cisplatin | USP/EP | GMP/EDMF | 
| 7 | Cladribine | USP | FDA approved | 
| 8 | Cyclophosphamide | USP/EP | FDA/COS approved | 
| 9 | Cytarabine | USP/EP | FDA/COS approved | 
| 10 | Dacarbazine | USP | GMP/EDMF | 
| 11 | Dactinomycin | USP | FDA approved | 
| 12 | Daunorubicin hcl | USP/EP | FDA approved | 
| 13 | Docetaxel | Enterprise standard | GMP/EDMF | 
| 14 | Doxorubicin hcl | USP/EP | DMF/COS approved | 
| 15 | Epirubicin hcl | EP | DMF/COS approved | 
| 16 | Floxuridine | USP | FDA approved | 
| 17 | Etoposide | USP | FDA approved | 
| 18 | Fluorouracil | USP | GMP/DMF | 
| 19 | Fludarabine phosphate | USP,EP | FDA/COS approved | 
| 20 | Fulvestrant | Enterprise standard | GMP/EDMF | 
| 21 | Gemcitabine hcl | EP | FDA approved | 
| 22 | Glufosfamide | Enterprise standard | GMP | 
| 23 | Granisetron hcl | USP, EP | FDA/COS approved | 
| 24 | Idarubicin hcl | USP | FDA approved | 
| 25 | Ifosfamide | USP | FDA approved | 
| 26 | Irinotecan hcl | USP | GMP+EDMF | 
| 27 | Letrozole | USP/ EP | GMP+EDMF | 
| 28 | Leucovorin calcium | USP/EP | FDA approved | 
| 29 | Leuprolide acetate | EP | EDMF | 
| 30 | Mesna | EP | GMP/FDA/EDMF approved | 
| 31 | Methotrexate | USP/EP | COA approved | 
| 32 | Mitomycin | USP/EP | FDA/COS approved | 
| 33 | Octreotide acetate | EP | EDMF | 
| 34 | Oxaliplatin | EP | COS approved | 
| 35 | Paclitaxel | USP | EDMF | 
| 36 | Pfirarubicin | Enterprise standard | TDP | 
| 37 | Pemetrexed disodium | Enterprise standard | GMP/EDMF | 
| 38 | Tamoxifen citrate | USP,EP | EDMF | 
| 39 | Valrubicin | Enterprise standard | TDP | 
| 40 | Vinblastine sulphate | USP | GMP+DMF | 
| 41 | Vincristine sulphate | USP,EP | GMP+DMF | 
| 42 | Vinorelbine tartrate | USP,EP | FDA/COS approved | 
| Nota: Los productos cubiertos por una patente en el país de destino no será suministrado a este país. Sin embargo, la responsabilidad final y el riesgo recae en el comprador. | 



